InnoCare Pharma (SEHK:9969) Wins IND Approval, Is The Upside Already Priced In?

The recent approval of InnoCare Pharma (SEHK:9969)’s IND application for ICP-B381 by China’s drug regulator gives investors a new clinical asset to watch in the company’s antibody drug conjugate pipeline.

That IND approval landed after a strong run in InnoCare Pharma’s share price, with a 90-day share price return of 42.66% and a year-to-date share price gain of 22.80%, even though the 1-year total shareholder return declined 12.59% and the 5-year total shareholder return fell 25.67%.

Scan the ADC space alongside InnoCare Pharma by comparing it with 131 healthcare AI stocks that are already pushing the boundaries of tech-enabled drug development.

InnoCare Pharma now has a richer oncology pipeline and a share price that has already reacted. The real tension is whether that recent excitement still leaves room on valuation or fully reflects it.

Most Popular Narrative: 22% Undervalued

On the most followed narrative, InnoCare Pharma screens as undervalued, with a fair value of HK$19.62 against a last close of HK$15.35. The IND news therefore lands on top of a story that already leans positive on price versus modelled worth.

The analysts have a consensus price target of HK$19.62 for InnoCare Pharma based on their expectations of its future earnings growth, profit margins and other risk factors. Despite analysts expecting the underlying business to decline, they seem to believe it’s more valuable than what the market thinks.

See why 1 investors see InnoCare Pharma as 22% undervalued.

Result: Fair Value of HK$19.62 (UNDERVALUED)

Still, the bullish InnoCare Pharma story can unravel if heavy R&D spending fails to translate into successful launches, or if rival therapies erode key product demand.

Find out about the key risks to this InnoCare Pharma narrative.

Another View: InnoCare Pharma On Earnings Multiples

The share price story looks different when you switch from fair value models to straight earnings multiples. InnoCare Pharma trades on a P/E of 24.2x, compared with a fair ratio of 9.7x, the Hong Kong Biotechs average of 16.8x, and a peer group at 17.9x.

That gap points to investors paying a richer price for each dollar of earnings than both the sector and the fair ratio suggest. This can mean less room for error if forecasts on margins or product uptake fall short. The question is whether you think the pipeline and ADC ambitions justify that premium or not.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Mixed signals on InnoCare Pharma so far. If you want to move quickly and build your own view off the data, start by weighing the 4 key rewards and 3 important warning signs.

Looking For More Investment Ideas Beyond InnoCare Pharma?

If InnoCare Pharma has sharpened your appetite for opportunities, do not stop here. Broaden your watchlist with other ideas that match your risk and return preferences.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com